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Abstract
Background: Cancer-related immune antigens in the tumor microenvironment could represent an obstacle to
agents targeting EGFR “cetuximab” or VEGF “bevacizumab” in metastatic colorectal cancer (mCRC) patients.
Methods: Infiltrating immune cells into tumor tissues, cancer-related expression of immune antigens (CD3, CD8,
CD68, CD73, MPO, CD15/FUT4) from 102 mCRC patients receiving first-line Cetuximab or Bevacizumab plus
chemotherapy were assessed by immunohistochemistry and validated in an independent tissue microarrays of
140 patients. Genome-wide expression profiles from 436 patients and 60 colon cancer cell lines were investigated
using bioinformatics analysis. In vitro kinase assays of target genes activated by chemokines or growth factors were
performed.
Results: Here, we report that cancer-related CD15/FUT4 is overexpressed in most of mCRCs patients (43 %) and
associates with lower intratumoral CD3+ and CD8+ T cells, higher systemic inflammation (NLR at diagnosis >5)
and poorer outcomes, in terms of response and progression-free survival than those CD15/FUT4-low or negative
ones (adjusted hazard ratio (HR) = 2.92; 95 % CI = 1.86–4.41; P < 0.001). Overexpression of CD15/FUT4 is induced
through RAF-MEK-ERK kinase cascade, suppressed by MEK inhibitors and exhibits a close connection with constitutive
oncogenic signalling pathways that respond to ERBB3 or FGFR4 activation (P < 0.001). CD15/FUT4-high expressing colon
cancer cells with primary resistance to cetuximab or bevacizumab are significantly more sensitive to MEK inhibitors
than CD15/FUT4-low counterparts.
Conclusion: Cancer-related CD15/FUT4 overexpression participates in cetuximab or bevacizumab mechanisms of
resistance in mCRC patients. CD15/FUT4 as a potential target of the antitumor immune response requires further
evaluation in clinical studies.
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Introduction
In the last decade, metastatic colorectal carcinoma
(mCRC) treatment has radically improved, thanks to the
introduction, into clinical practice of novel agents target-
ing EGFR and VEGF pathways [1–5].
Cancer is driven by activating mutations and aberrant
signal transduction node, most of which (RAS, PTEN,
EGFR) play a significant role in the prediction of resist-
ance to epidermal growth factor receptor (EGFR) mono-
clonal antibodies in mCRC treatment, whereas,
equivalent reliable predictors of bevacizumab are cur-
rently lacking [1, 2, 6, 7]. Current data provide evidence
for extensive autocrine and paracrine EGFR-VEGF (R)
cross-talk in both tumor and tumor-associated micro-
environment underlining the potential interest in target-
ing both pathways [1–4]. Although clinically distinct
subtypes of CRC are starting to emerge, the factors de-
termining whether a patient will have a response to
target-oriented therapy remain still elusive [7, 8].
A tumor grows in an intricate network of epithelial
cells, vascular and lymphatic vessels, cytokines and che-
mokines, and infiltrating immune cells named the tumor
microenvironment [9–11]. Increasing studies underscore
the involvement of immune cells, through an emerging
hallmark of cancer, evoked as evasion of immune sur-
veillance [9–11]. In keeping with this concept, a higher
infiltration of memory cytotoxic Th1 T-lymphocytes and
tumor-associated neutrophils (TANs) correlate with a
longer survival, evidencing the critical effect of host im-
mune response on tumor evolution and clinical outcome
[11–16]. Unfortunately, tumor develops multiple mecha-
nisms of evading immune responses, by forming a com-
promised microenvironment that contrasts the effects of
therapeutic agents [10, 17–19]. We have recently pro-
posed that malignant cells can “express” ectopic immune
epitopes, which are typical of immune cells (i.e., CD73,
CD68) and that these may serve as tumor antigens to
evade immune surveillance facilitating homotypic inter-
actions in distant organs during metastatic process [20].
The connection between immune neoantigens expressed
on tumor cells and benefits to target therapies has re-
ceived little attention so far. In this study, we investi-
gated the relationship between inflammatory response,
tumor immune-phenotypic features and patients’ out-
come receiving first line cetuximab or bevacizumab plus
chemotherapy schedules. Herein, we provide evidence
that the “don’t eat me” signal CD15/FUT4 on cancer
cells associates with decreased benefit to target therapy.
CD15/FUT4 overexpression is driven by constitutive
oncogenic signalling pathways in the tumor cells (innate
immune resistance) acting as a novel RAF-MEK-ERK
kinase downstream regulator through ERBB3 or FGFR4
activation, respectively. The results presented here could
help to identify a subset of CD15/FUT4-overexpressing
patients who have higher chances of benefiting from
MEK inhibitors.
Patients and methods
Patient population and samples
To study the relationship between tumor-associated im-
mune infiltration and responses to targeted therapies, be-
tween 2010–2014 a retrospective cohort of metastatic
CRC patients from two institutions: Medical Oncology
Unit of Sacro Cuore di Gesù, Fatebenefratelli Hospital,
Benevento (Italy) and Department of Oncology and Path-
ology, Mater Salutis Hospital, Legnago Verona, (Italy)
were recruited. The cohort was partitioned into a dis-
covery and validation set, resulting in a total of (n = 102)
patients receiving the target-agents Cetuximab or Beva-
cizumab plus chemotherapy based schedules (FOLFOX,
XELOX or FOLFIRI) first-line therapy. Ethical, legal, and
social implications were approved by an ethical review
board of Fatebefratelli Hospital Institution. Formalin-
fixed, paraffin-embedded (FFPE) tumor tissues were re-
trieved, anonymized and areas of tumor revaluated on
hematoxylin and eosin–stained sections. For systemic
inflammatory response, the neutrophil-to-lymphocyte
ratio (NLR) was calculated from routine complete
blood on the same day of primary surgery. Study end-
points were represented by evaluation of patients’ out-
come in terms of objective response (primary
endpoint), progression free survival (PFS) and overall
survival (OS). The best overall response was evaluated
every 8 or 12 weeks. Tumor response was classified in:
complete response (CR), partial response (PR), stable
disease (SD), and progressive disease (PD) according
to Response Evaluation Criteria in Solid Tumors
(RECIST). Consequently, patients with CR, PR and
SD ≥ 6 months were considered responders while the
remaining nonresponders. Details of patients’ outcome
evaluation are provided in (Additional file 1: Table S1
and Additional file 2).
An independent cohort, named as validation series II
consisting of 140 stage I-IV primary CRCs collected con-
secutively was then evaluated [21, 22]. They represented a
continuous, unselected TMAs cohort of patients with
molecular, histopathological and clinical findings (OS)
recruited during the period 2003–2009. The NLR ratio
was collected on the same day of primary surgery for
routine laboratory analysis through the full blood count as
indicated above. The complete workflow of the study is
summarized in (Additional file 3: Figure S1). Details about
this data set are provided in (Additional file 1: Table S2
and Additional file 2).
Immunohistochemistry
Following pathologic review for diagnostic confirmation
and exclusion of highly fibrotic or necrotic tumor
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sections, whole-blocks 4-μm sections were incubated
with antibodies listed in (Additional file 1: Table S3).
The 3,3’ diaminobenzidine and haematoxylin were used
as chromogen and counterstain, respectively. Tumor-
associated infiltrating immune cells and cancer-related
expression were identified using staining positivity ana-
lysis. Infiltrating immune cells from different tumor lo-
cations, were quantified by using ImageJ-based software,
while intraepithelial immune cells were counted manu-
ally. All the cell counts were expressed as cells mm−2.
The data were obtained from two whole sections per tis-
sue and at least 500 epithelial cells and 500 infiltrating
immune cells were analyzed per section. The proportion
of cancer cells staining was scored in 3 s grades regard-
less of intensity as follows: 1) Negative staining (Neg)
was defined as the complete absence of staining in more
than 95 % of tumor cells; 2) Partially positive or (low
expression) characterized by a limited number of
tumor cells scattered in a background of either nega-
tive or positive tumor cells. 3) Diffuse positivity (High
expression) corresponding to a homogeneous mem-
brane staining in virtually all tumor cells. Details on
immunohistochemistry (IHC) evaluation is provided
in (Additional file 2).
Bioinformatics analysis and independent gene expression
profile data sets
The following genome-wide expression data sets were
analyzed by using in silico bioinformatics approaches:
a) GSE17536/GSE17537 of 226 patients; b) colorectal
Cancer Genome Atlas (TCGA) of 210 patients; c) Cancer
Cell Line Encyclopedia, Broad Institute/Novartis of 60
CRC cell lines: d) metastatic CRC cell line “SW480”
with primary resistance to cetuximab and treated with
MEK inhibitor (AZD6244, Selumetinib), GEO Omnibus
[7, 23–25]. The IC50, a direct indicator of drug effi-
cacy, for six CRC cell lines, CD15/FUT4-high (HT29,
LoVo, SW620) and CD15/FUT4-low (SW480, HCT116,
SW48 and GEO) treated with MEKi BAY 86–9766,
Selumetinib or Pimasertib was publically available
and calculated according to the reported data [26].
Details about in silico analysis is provided in (Additional
file 2).
CRC derived cell lines and qRT-PCR validation
A series of 12 representative CRC-derived cell lines,
“purchased from American Type Culture Collection
(ATCC, Rockville, MD)” were grown in DMEM (Life
Technologies, Grand Island, NY, USA) or RPMI 1640
medium plus 10 % FBS (Life Technologies) without
antibiotics/antimycotics. All the cell lines were con-
firmed to be negative for mycoplasma by PCR
(Venor GeMkit,Sigma-Aldrich, St. Louis, MO, USA)
prior to use. Cells were cultured in a humidified 37 °C
incubator at 5 % CO2. Total RNA from cell lines was ex-
tracted using miReasy kit (Qiagen, Hombrechtikon,
Switzerland) and cDNA was generated using Superscript
reverse transcriptase (Life Technologies, Grand Island,
NY, USA). The concentration of cDNA was deter-
mined (Nanodrop 2000, Thermo Scientific, Asheville,
NC, USA) and 25 ng of total cDNA was subjected to
quantitative PCR using QI Agility (automated PCR
setup, Qiagen), Quanti Tect SYBR Green PCR kit
(Qiagen), and Rotor-Gene Q (Qiagen) real-time PCR
machine and gene specific primers (Additional file 1:
Table S4). The gene-specific copy number was calcu-
lated according to the standard curve and normalized
to the amount of cDNA (ng) in the reaction. All PCR
reactions were performed in triplicate and expression
levels were computed as reported [20, 21, 27].
Reagents, transcript induction and kinase assays
CRC cells were then grown to 70 % of confluence,
serum starved for 24 h, and stimulated for 8 h with
10 nM EGF (R&D System), 20U/ml IL-1beta (Peprotech),
or for 30 min with 200U/ml IL-10 or 50 ng/ml IL-6
(R&D System). Subsequently, the cells were harvested
for RNA (qRT-PCR see above) or protein extraction.
Western blot was performed according to the pub-
lished procedures [20, 21, 27]. A ratio of normalized
ERK1/2 (pERK/total ERK1/2), Stat3 (pStat3/total
Stat3) and stat1 (pstat1/total Stat1) was calculated for
monitoring expression and phosphorylation levels.
Human polymorphonuclear cells (PMN) and peripheral
blood mononuclear cells (PBMC) purified from buffy
coats of healthy donors were used as positive control for
kinase assays [27]. Details on western-blot and kinase as-
says are provided in (Additional file 2).
Statistical analysis
Statistical analyses were conducted by using R statis-
tical software and SPSS version 15 Windows, SPSS
Inc, Chicago, IL and GraphPad Prism 5. Data are pre-
sented with medians and ranges. Association between
IHC expression and clinico-pathological data was
assessed using Spearman r correlation or χ2 test. The
Wilcoxon–Mann–Whitney or Kruskal-Wallis nonpara-
metric tests were used to identify markers with a sig-
nificantly differentexpression among patient groups.
Kaplan-Meier curves were used to visualize differ-
ences between PFS and OS. Significance among pa-
tient groups was calculated by using the log-rank test.
Prognostic and predictive effects were assessed using
PFS and OS as clinical endpoints. The predictive per-
formance of each individual marker was considered
alone and together (CD15/FUT4 IHC and NLR at
diagnosis). We used Cox proportional hazardsmodel
to determine hazard ratios (HRs) with 95 % of
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confidence interval. The HRs were corrected through
multivariate analysis, adjusting for other factors previ-
ously shown to be prognostic in the population study.
All tests were two-sided, and a P < .05 was considered
statistically significant. The (Additional file 2) illus-
trates further details about the statistical and valid-
ation methods used.
Results
Relationship among inflammatory cell infiltration,
immune-phenotypic traits expressed by cancer cells and
therapy response
In the initial discovery set, peritumoral inflammatory in-
filtrate was, in general, heavier than intratumoral and
stromal infiltrate. The CD3+ T cells were the most abun-
dant in all tumor locations (at the invasive front, stroma
and intraepithelial), followed by infiltrating CD68+
monocyte–macrophage and CD15/FUT4+ neutrophils,
respectively (Fig. 1a).
Next, to distinguish between inflammatory infiltrate
and tumor immune-phenotypic traits, we examined the
presence of positivity in malignant cells including a lar-
ger series of immune markers (Fig. 1b and Additional
file 3: Figure S2A,B). Overall, we observed that the neu-
trophil antigen CD15/FUT4 was positive in the majority
of cases. Among the 32 tumors of the discovery set, 23
(72 %) of CD15/FUT4-positive tumors were classified as
low or high and had a higher recurrence than other
tumor-related immune antigen i.e., CD68, CD73
(Fig. 1b, c and Additional file 2: Figure S2A). Using
myeloperoxidase (MPO) as an additional marker of
mature neutrophils, we did not detect positivity on
malignant cells. In line with this, CD15/FUT4 marked
infiltrating granulocytes but not epithelial colonic cells
in matched normal adjacent mucosa (Fig. 1c and
Additional file 3: Figure S2A, B). Tumors displaying high
CD15/FUT4 expression showed a trend towards: a) lower
peritumoral immune-cells density and elevated NLR at
diagnosis; b) poorer patients’ outcome both in terms of re-
sponse to first line therapy and progression free survival
(Fig. 1b-d and Additional file 3: Figure S2C, D).
Prognostic significance of tumor-related CD15/FUT4
overexpression and inflammatory response
To corroborate CD15/FUT4 cancer-related alteration
and its relationship with inflammatory response and pa-
tients’ outcome, we analyzed 70 additional samples,
resulting in a total of 102 patients. Additional file 1:
Table S1 summarizes clinico-pathological features of the
entire study cohort.
Linear correlation analysis showed that high systemic
inflammation is associated with lower immune-cells
density, especially CD3+T cells (r =0.15; P < 0.01). A
finding further supported by decreased infiltration of
CD8+ for cytotoxic T cells (r = 0.26; P < 0.001; Fig. 2a
and Additional file 3: Figure S2C, D).
CD15/FUT4 expression had a significant direct correl-
ation with systemic inflammatory response at diagnosis.
The median values of NLR ranged from 5.71 for CD15/
FUT4-neg, 6.60 for CD15/FUT4-low and 10.5 for CD15/
FUT4-high expressing tumors, respectively (P < 0.05;
Fig. 2b and Additional file 3: Figure S3A). This indicated
that when CD15/FUT4 increases in malignant cells,
CRC inflammatory infiltrate declines and systemic in-
flammation at diagnosis increases.
We then associated cancer-related expression of
CD15/FUT4 with patients’ outcome in terms of Re-
sponse and Survival (PFS and OS).
Among 102 assessable tumor specimens, 31 out of
44, (70 %), 8 out of 40 (20 %) and 1 out of 18 (6 %)
of the CD15/FUT4-high, low and negative tumors
were considered nonresponders to the therapy, re-
spectively (P = 0.00000532; Table 1).
PFS was significantly different according to CD15/
FUT4 expression on malignant cells: mPFS was 5.5 vs
10 and 13 months, in patients with CD15/FUT4-high,
low and negative tumors, respectively (HR = 3.37; 95 %
CI = 2.14–5.51; P < 0.0001, Fig. 2c). Accordingly, median
OS was 13 vs 26 and 38 months in patients with CD15/
FUT4-high, low and negative tumors, respectively
(HR = 1.95; 95 % CI = 1.37-2.98; P =0.001, Fig. 2c).
Concordance for systemic inflammatory response at
time of diagnosis and clinical response was also significant
(Additional file 3: Figure S3B). Thirty-eight out of 72
(53 %) with NLR >5 and 2 out of 30 (7 %) patients with
NLR ≤ 5 were considered nonresponders, respectively
(P = 0.00012545; Table 1). Median PFS was 6.5 vs
12 months in patients with NLR >5 vs ≤ 5, respectively
(HR = 2.41; 95 % CI = 1.37–4.32; P = 0.002). Median mOS
was 17 vs 35 months in patients with NLR >5 vs ≤ 5, re-
spectively (HR = 2.39; 95 % CI = 1.48–3.85; P < 0.0001;
Fig. 2d).
Multivariate Cox regression analysis revealed that sys-
temic inflammation at diagnosis and KRAS mutation were
independent prognostic factors for OS, whereas CD15/
FUT4, and marginally systemic inflammatory response
were independent predictors of PFS after adjustment for
therapeutic regime (Table 2). The stratification of patients
who presented both positive characteristics revealed that a
large proportion (32 out of 40; 80 % of patients) among
the nonresponder subgroup had the combination CD15/
FUT4high/NLR>5(Additional file 3: Figure S3C).
Tumor-related CD15/FUT4 expression and associated
molecular parameters in an independent TMAs validation
set of stages I-IV CRCs
This independent cohort confirmed CD15/FUT4 positiv-
ity in the majority of carcinomas (76 %; 107 out of 140).
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High, low and negative expression was identified in 58
out 107 (54 %), 49 out of 107 (46 %), and 33 out of 107
(24 %) of cases, respectively (Additional file 1: Table S2
and Additional file 3: Figure S4A). Tumors displaying
CD15/FUT4-high expression pattern were more fre-
quently associated with advanced tumor stage III and IV
and with lower-densities of CD3+ and CD8+ T cells
peritumoral infiltrate, confirming the data obtained on
the first series (Additional file 3: Figure S4B). Tumors
displaying this pattern were also frequently MMR profi-
cient and TP53 and KRAS mutated than CD15/FUT4-
negative one (Additional file 1: Table S3). We tested
whether the combination CD15/FUT4 and NLR had im-
pact on patients’ prognosis also in this series. Indeed, the
combinations CD15NegNLR≤5 and CD15highNLR>5robustly
stratify the cohort into two groups with 100 % and 33.1 %
of survival rate at 5 years after diagnosis, respectively.
(Additional file 3: Figure S4C, D).
CATEGORY Variable Responder NonResponder
Blood
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CD15/FUT4 20 470 152 302 21 160 450 192 78 20 80 200 98 18 200 8 15 15 153 10 230 63 80 15 100 28 5 30 5 18 43 25































Fig. 1 Tumor-associated inflammatory infiltrate, systemic inflammatory response and therapeutic response in the discovery set of mCRC.
a Tumor-associated quantification of individual cell types, CD3+ T cells, CD68+ monocyte-macrophage cells, CD15/FUT4+ neutrophils
(n = 32) considering all tumor locations (invasive front, stroma and intraepithelial). One dot represents mean of five replicates cells counts,
expressed as cells mm−2. Bars represent medians (200, 140 and 56.5 cells counts, respectively). b Clustering analysis according to the
patients’ best response to first line therapy. Interrelationship among, quantification of four types of inflammatory cells, systemic inflammatory
response (NLR at time of diagnosis), tumor-related expression of immune markers including (CD73) and KRAS mutational status in each patient
of the discovery set. Tumor infiltrating immune-cells include an additional one, MPO+ for neutrophils granulocytes). Immune-positivity on
malignant cells is expressed as negative (green), low (blue) and high (red) (see methods for score details). Of note, all patients progressing to
first line therapy overexpressed CD15/FUT4 on cancer cells. c Representative pictures for CD15/FUT4 IHC in normal mucosae and tumor
specimens, respectively. CD15/FUT4 marks intensely neutrophils granulocytes (red arrows) but not or weakly colonic epithelial cells in
normal mucosa (black arrow). Cancer-related CD15/FUT4 expression pattern detected in tumors: red arrows indicates stromal compartment,
black arrows indicate malignant cells. d Relationship between cancer-relatedCD15/FUT4 expression pattern (negative, low and high subgroups)
and Progression-Free Survival (PFS) after first line therapy. Distribution of PFS expressed in months, into subgroup CD15/FUT4-high, low
and negative tumors, respectively. Bars represent medians (13, 11 and 7.5 months, respectively). Abbreviations: neutrophil-to-lymphocyte
ratio, NLR
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Genomic variations related to CD15/FUT4 overexpression
To gain insights into the mechanisms that regulate
CD15/FUT4 expression, we collected two independent
publicly available gene-expression datasets involving a
total of 436 colorectal cancer and 60 colon cancer cell
lines [7, 23, 24]. Strikingly, in-silico analysis, inferred a
number of 1350 interactions and 20 regulons CD15/
FUT4-associated, and revealed a series of disease-
relevant pathways: a) prosurvival; b) immune-evasion;
c) protein kinase cascade and viral infectious response
closely connected to the efficacy of drugs (Fig. 3a and
Additional file 3: Figure S5A-D) [28–30]. CD15/FUT4
transcript was significantly higher in tumor tissues than
normal control in TCGA series comprising 210 CRCs and
22 and normal colorectal mucosa specimens, respectively
(Fig. 3b). We further confirmed the association between
CD15/FUT4 overexpression and cancer recurrence in
the GSE17536/GSE17537 series (n = 226), for which
Table 1 Response to treatment according to CD15/FUT4-IHC on primary tumors and NLR at diagnosis
CD15/FUT4-IHC NLR at diagnosis
Therapeutic response Neg Low High P NLR ≤5 NLR >5 P
Frequency N (%) N (%) N (%) 0.00000532 N (%) N (%) 0.00012545
Responder 17 (94) 32 (80) 13 (30) 28 (93) 34 (47)
Nonresponder 1 (6) 8 (20) 31 (70) 2 (7) 38 (53)
Total 18 (100) 40 (100) 44 (100) 30 (100) 72 (100)
Abbreviation: IHC immunohistochemistry, NLR blood neutrophil-to-lymphocyte ratio
A B
C D




CD15/FUT4 (IHC) CD15/FUT4 (IHC) NLR at diagnosis 









Fig 2 CD15/FUT4 expression pattern, inflammatory response and patients’ outcome in a larger cohort study. a Significant inverse correlation of
NLR at diagnosis with tumor-associated CD3+ T-cells and CD8+ T- cytotoxic quantification (n = 99; expressed as mean of replicates cells counts,
cells mm−2). b Correlation between NLR at diagnosis and tumor-related expression pattern of CD15/FUT4 spared into three subgroups negative,
low and high, respectively. One dot represents NLR at diagnosis for each patient, P value was obtained by Mann–Whitney test. c Kaplan–Meier
curves for progression-free survival and overall survival in the validation set (n = 102). The medians PFS value were 13, 10 and 5.5 months (HR = 3.37;
95 % CI = 2.14–5.51). The medians OS value were 38, 26 and 13 months for negative (n = 18), low (n = 40) and high-CD15/FUT4 (n = 44) expressing
tumors, respectively (HR = 1.95; 95 % CI = 1.37–2.98). d Kaplan–Meier curves for progression-free survival and overall survival in relationship with NLR at
diagnosis (cutoff value of 5). The medians PFS value were 12 and 6.5 months respectively (HR = 2.41; 95 % CI = 1.37–4.32). The medians OS value were
35 and 17 months with an NLR ≤5 (n = 30) and an NLR >5 (n = 72) patients respectively(HR = 2.39; 95 % CI = 1.48–3.85)
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reported follow-up data were available (Additional file 3:
Figure S6A, B) [23]. In this cohort, CD15/FUT4 overex-
pression was associated with short time-to-recurrence
(TTR) but not with OS, independently from initial tumor
stage (Additional file 3: Figure S6B). CD15/FUT4
transcripts were significantly higher in chromosomal in-
stability (CIN) positive than CIN-negative tumors. Its up-
regulation was associated to relevant genetic aberrations
such as: ERBB2, ERBB3 and FGFR4 overexpression, a
finding confirmed in a large series of 60 CRC cell lines
(Fig. 3b and Additional file 3: Figure S6A-C).
CD15/FUT4 overexpression and MEK inhibitor responses
in CRC cell lines
We then tested this observation by performing qRT-PCR
assays on a panel of CRC cell lines. This analysis revealed
that CD15/FUT4 overexpression is tightly correlated
with ERBB3 and FGFR4 transcript but not with EGFR.
Of note, expression of CD15/FUT4 on the surface of
tumor cells indicated a good concordance with transcript
levels (Fig. 3c). Based on these observations, to verify
whether CD15/FUT4 could be regulated by kinase cas-
cade, we treated RKO and SW480 CRC cells with EGF or
IL1β for 8 h. Following exposure to EGF or IL1β, we ob-
served a consistent induction of CD15/FUT4 transcript
through ERK1/2 phosphorylation (Fig. 3d). In contrast,
IL10 or IL6- STAT1/STAT3 dependent phosphorylation
did not cause CD15/FUT4 overexpression (Fig. 3d). To
further confirm CD15/FUT4 as a RAF-MEK-ERK kinases
downstream effector, we used two recently published
gene expression data sets [25, 26] derived from meta-
static CRC cell lines, “with primary resistance to cetuxi-
mab” querying for MEK inhibitor (MEKi) responsive
genes (Fig. 4a). We found that CD15/FUT4 transcript
was significantly downregulated following “Selumetinib”
treatment (FDR < 0.01 related to untreated control) and
showed a high level of synergy with gene signature
related to the prosurvival and evasion of immune surveil-
lance (Fig. 4a, b). To further demonstrate that MEKi
growth inhibition effect was dependent on CD15/FUT4
expression levels, we used public data from three selective
MEK inhibitors, BAY 86–9766, Selumetinib and Pimaser-
tib in a panel of six CRC cell lines. We observed that both
“Selumetinib and Pimasertib” were highly effective in
CD15/FUT4-high expressing CRC cells with intrinsic re-
sistance to cetuximab or bevacizumab, as compared to
those with CD15/FUT4-low expression one (Fig. 4c).
Discussion
Much effort is currently focused on attempts to target
several signaling pathways at the same time. The
extensive degree of EGFR-VEGF(R) pathway cross-talk
identifies them as particularly promising for joint target-
ing [3, 29]. In addition to RAS gene family mutations, a
number of studies suggest that intracellular downstream
effectors of these pathways or immune inflammatory
microenvironment could be correlated with primary re-
sistance in metastatic tumors [1–5, 10]. Tumor micro-
environment not only plays a pivotal role during cancer
progression and metastasis but also has profound effects
on therapeutic efficacy [10–13, 17–19]. According to this
assumption, immune checkpoint inhibitors are promising
new approaches for tackling solid tumors [31–33].
In this study, we investigated candidate determinants
of resistance related to the immune tumor microenvir-
onment and inflammatory response, using as proof of
principle two mainstay of first line treatment for meta-
static CRC anti-EGFR cetuximab, anti-VEGF bevacizu-
mab based therapy. Surprisingly, among a panel of
immune markers, we uncovered that a large proportion
of tumors overexpressed CD15/FUT4 neuthrophil anti-
gen. Strikingly, this expression pattern associated with
short disease control and rapid disease progression.
CD15/FUT4-high expressing tumors showed lower
Table 2 Univariate and multivariate analysis for PFS and OS. Cox’s regression model taking into account the IHC data or NLR
at diagnosis
Variable Univariate (OS) P value Multivariate (OS) P value
NLR >5 vs NLR ≤5 2.39 (1.48–3.85) 0.0001** 1.99 (1.2–3.3) 0.007**
RAS Mut vs WT 2.07 (1.28–3.34) 0.003 ** 1.88 (1.16–3.06) 0.01*
Multiple vs single metastases 1.34 (0.99–1.81) 0.056 1.30 (0.91–1.86) 0.13
CD15/FUT4 high vs low/neg 1.95 (1.37–2.98) 0.001** 1.55 (1.06–2.89) 0.056
Variable Univariate (PFS) P value Multivariate (PFS) P value
NLR >5 vs NLR≤ 5 2.41 (1.37–4.22) 0.002** 2.47 (1.4–4.34) 0.05*
Stage at diagnosis III and IV vs II 1.42 (1.05–1.91) 0.021* 1.3 (0.928–1.81) 0.127
Histotype mucinous vs others 1.60 (1.0–2.57) 0.05* 1.43 (0.89–2.32) 0.136
CD15/FUT4 high vs low/neg 3.37 (2.14–5.51) 0.0001** 2.92 (1.86–4.61) 0.001**
Abbreviations: HR Hazard ratio, 95 % CI 95 % confidence interval, IHC Immunohistochemistry, NLR blood neutrophil-to-lymphocyte ratio
*P ≤ .05; **P ≤ .01
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intratumoral immune density of both innate (CD68+,
CD15+ and MPO+ macrophages and Neutrophil cells)
and especially adaptive (CD3+ and CD8+) immune T-cell
subsets. The concordance with NLR at diagnosis, sug-
gested that CD15/FUT4 overexpression on malignant cells
could connect peritumoral immune suppression and ele-
vated systemic inflammatory response. Patients with
tumors harboring CD15/FUT4-high expression were asso-
ciated with worse PFS both in univariate and multivariate
analysis, indicating CD15/FUT4 as a possible marker of
decreased therapy response, a finding further strength-
ened by an elevated blood inflammatory response
(NLR > 5). Therefore, the progressive decrease of immune
cell densities along with CD15/FUT4 overexpression and
Fig. 3 Genome-wide expression analysis identifies CD15/FUT4 as a novel RAF-MEK-ERK kinase downstream target. a The most enriched network of
CD15/FUT4 regulators is depicted comprising 20 regulons and two closely connected upstream genes involving EGFR and FGFR pathways
(see Additional file 2 and Additional file 3: Figure S5 for more information). The gene expression datasets GSE17536/GSE17537 series (n = 226)
were analyzed simultaneously with the ARACNe algorithm to infer transcriptional regulatory network fromgenome-wide expression profiles
CD15/FUT4-connected. b CD15/FUT4 expression in CRC using patient-matched tumor-normal data available from TCGA. The P value refers to
Mann–Whitney test. Expression profiles of ERBB1, ERBB2, ERBB3, FGFR4, CD15/FUT4 and KRAS mutant across a series of CRC cell lines (n = 60) by
applying a fold change of gene expression microarray data of 1.5 and subdivided on the basis of chromosomal instability calculated as fraction
of copy-number alteration pattern (form 0 to 0.922). Significant correlation between CD15/FUT4, ERBB3 and FGFR4 expression levels. c Linear
correlation between ERBB3, FGFR4 and CD15/FUT4 transcript levels is validated in our independent series of (n = 12) CRC cell lines. Immunofluorescence
labeling “green” of nonpermeabilize cancer cells shows differential expression of CD15/FUT4 “arrows,” on the cell plasma membrane of RKO and HT29,
respectively. To visualize nuclei, the merged images were stained with 4’6-diamidino-2-phenylindole (Dapi), “blue”. d CD15/FUT4-dependent transcript
induction by EGF (10 nM) or IL1b (20U/ml) by using 0.1 % of DMSO as vehicle, in two representative CRC cell lines SW480 and RKO, respectively. Cells
were treated for 8 h and the ratio anti-p-ERK/ERK1/2 was quantified by western-blot analysis. The treatment with IL-10 (200U/ml) or IL-6 (50 ng/ml) for
30 min revealed a significant induction of IL6-STAT1/STAT3 dependent phosphorylation in a panel of 4 CRC cell lines as detected by western-blot
analysis. Mononuclear cells (Mono) purified from buffy coats of healthy donors were used as positive control for IL10-STAT3 dependent
phosphorylation. CD15/FUT4 transcript did not reveal any significant induction following IL10 or IL6 at 48 h of treatment. The P value
were obtained by Mann–Whitney test; *P ≤ .05; **P ≤ .01
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increased inflammatory response could provide a clinical
context of tumor progression, explainable as a pro-
nounced immune-escape mechanism. Our observations
however have a number of limitations in particular be-
cause patients had received two treatments targeting dif-
ferent pathways, and are few to support more general
conclusions, although the number can be considered
large (102) for an IHC study. In this regard, an inde-
pendent TMAs data set confirmed that high-CD15/FUT4
expressing tumors correlated with reduced density of the
immune infiltrates by CD3 and CD8 cells and elevated
blood inflammatory response, similarly to those seen in
the validation set I. We observed that CD15/FUT4-
expressing tumors had generally a well-differentiated
gene expression pattern (MMR proficient) and corre-
lated with subtypes enriched for TP53 and KRAS muta-
tions. These results evidenced that CD15/FUT4 could
serve as a surrogate marker to identify specific subtypes
Fig. 4 CD15/FUT4 transcript is repressed by MEK inhibitors in CRC cell lines with intrinsic resistance to cetuximab or bevacizumab. a Heat map
showing groups of differentially expressed genes or “responsive genes” to the MEK inhibitor “AZD6244, Selumetinib” (MEKi) or control, in a
metastatic, KRAS mutant and cetuximab-resistant CRC line “SW480”. Down-regulated expression of CD15/FUT4 in “Selumetinib” treated cells, shows
a high level of concordance with genes implicated in DNA replication (MCM) and immune-escape mechanisms (CD47, CD73) (gene signature a
and b, respectively). The gene signature (b) indicates MEKi upregulated genes mainly involved in cell-cycle arrest (CDKN) or tumor differentiation
(CDX2, CDH1, MUC1). b Number and distribution of differentially expressed genes (DEGs) between the MEK inhibitor responsive genes
and CD15/FUT4-related genes derived from (TCGA data set). c Six CRC cell lines, HT29, LoVo, SW480, SW620, HCT116, SW48 and GEO treated for
96 h with indicated MEKi are subdivided taking into account CD15/FUT4 expression levels. Results represent the mean of the IC50 ± SD determined by
interpolation from the dose response curves in CD15/FUT4-high (HT29, LoVo, SW480 and SW620) and CD15/FUT4-low (HCT116, SW48 and GEO)
expressing CRC cells. HT29, LoVo, SW480 and SW620 cells are known for intrinsic resistance (R) to cetuximab or bevacizumab. d Simplified model
showing CD15/FUT4 activation as a novel RAF-MEK-ERK signaling cascade downstream regulator. CD15/FUT4 could promote two mechanisms of
primary resistance to agents targeting EGFR and VEGF cell proliferation (prosurvival) and evasion of immune surveillance likely through several
pathways consisting of ERBB3, FGFR and IL1b cascade. The combined blockade of EGFR or VEGF with MEKi could represent a therapeutic strategy
for preventing and/or overcoming resistance of CD15/FUT4-overxpressing tumors
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with chromosomal instability for which has already been
proved lack of response to cetuximab and tendency to
metastasize [8]. Despite this, such evidence cannot explain
lack of response to agents targeting anti-EGFR and even
more to anti-VEGF. In this scenario, we performed in-
silico analysis across publically available gene-expression
data sets along with in vitro assays on derived colon can-
cer cell lines. Transcriptomic profiling confirmed that high
CD15/FUT4 transcript associated with CIN, KRAS
mutations and most importantly with ERBB3 and
FGFR4 overexpression but not ERBB1 (EGFR). These
results supported the hypothesis that consistent acti-
vation of CD15/FUT4 transcript acts downstream
and/or independently of EGFR or VEGFR pathways.
Interestingly, our findings are also consistent with re-
cent studies revealing that transcriptional induction of
ERBB3 acts as a prominent “hit” of intrinsic resist-
ance in CRC cell lines, while very little is known
about FGFR4 overexpression [34, 35]. Our observations
indicate that upregulation of FGFR4 may correlate with
intrinsic resistance to bevacizumab, as evidenced in HT29
and SW620 CRC cell lines, respectively.
Therefore, the novel role of CD15/FUT4 reflects per-
sistent genetic features of tumor cells rather than differ-
ences in immune infiltrates. Indeed, we demonstrate “in
vitro” that CD15/FUT4 transcript is induced through
MAPK-ERK kinase cascade. This finding was further
validated by querying for selective MEK inhibitor modu-
lated genes in cancer cell lines with KRAS or BRAF
mutations and primary resistance to cetuximab or beva-
cizumab, respectively. We observed that the MEK in-
hibitor “Selumetinib” caused a significant reduction of
CD15/FUT4 transcript, as a consequence, CD15/FUT4-
high expressing cancer cells were more sensitive to
“Selumetinib” and Pimasertib” than CD15/FUT4-low
counterparts.
Based on these findings, we proposed a model where
drug resistance could synergize on CD15/FUT4 through
at least two independent pathways: a) mitogenic intracel-
lular due to ERBB2/ERBB3 overexpression; b) pro-
angiogenic and/or mitogenic due to FGFR4 or IL-1β
released by an altered tumor microenvironment as sug-
gested by other studies (Fig. 4d) [35–37].
Our results suggest a possible rational for treating
CD15/FUT4-overexpressing mCRC through means of
IHC. In this subset, MEK inhibitors or dual inhibitors
that show strong synergy with MEK inhibition “i.e.,
cetuximab” could be effective for preventing and/or
overcoming primary resistance to cetuximab in CRC pa-
tients as recently reported in preclinical studies [34, 35].
CD15/FUT4 could also be dysregulated by tumors as an
important immune resistance mechanism similarly to
immune-checkpoint proteins. However, the relevance of
its molecular interactions to inhibit local antitumor T
cell-mediated response in the tumor microenvironment
remains obscure [38].
In conclusion, cancer-related CD15/FUT4 overexpres-
sion is associated with decreased benefit to target and
chemotherapeutic agents in metastatic tumors. CD15/
FUT4 acts as a downstream regulator of MAPK-ERK
pathway independently of EGFR or VEGF pathway, by
coupling mitogenic signaling cascade and immune-
escape mechanisms of metastatic tumors. Upregulation
of CD15/FUT4 on the tumor cell surface could repre-
sent a potential target to enhance antitumor effector
functions in the tumor microenvironment. In addition,
IHC assessment of CD15/FUT4 combined with RAS
mutation status could be a strategy to identify mCRC
patients who have higher chances of benefiting from tar-
geting and MEK inhibitor drugs. However, its role as a
potential biomarker susceptible to specific therapeutic
agents requires further evaluation in clinical setting.
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